Class information for:
Level 1: SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1001 2819 38.9 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
310 17755 CARCINOMA RENAL CELL//PARTIAL NEPHRECTOMY//NEPHRECTOMY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SUNITINIB Author keyword 355 46% 21% 585
2 METASTATIC RENAL CELL CARCINOMA Author keyword 172 62% 6% 180
3 CARCINOMA RENAL CELL Author keyword 109 12% 31% 861
4 SORAFENIB Author keyword 106 24% 14% 389
5 AXITINIB Author keyword 73 58% 3% 83
6 TEMSIROLIMUS Author keyword 61 39% 4% 122
7 PAZOPANIB Author keyword 56 44% 3% 97
8 CYTOREDUCTIVE NEPHRECTOMY Author keyword 55 77% 1% 37
9 TYROSINE KINASE INHIBITORS Author keyword 33 11% 10% 288
10 RENAL CELL CANCER Author keyword 27 20% 4% 119

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 SUNITINIB 355 46% 21% 585 Search SUNITINIB Search SUNITINIB
2 METASTATIC RENAL CELL CARCINOMA 172 62% 6% 180 Search METASTATIC+RENAL+CELL+CARCINOMA Search METASTATIC+RENAL+CELL+CARCINOMA
3 CARCINOMA RENAL CELL 109 12% 31% 861 Search CARCINOMA++RENAL+CELL Search CARCINOMA++RENAL+CELL
4 SORAFENIB 106 24% 14% 389 Search SORAFENIB Search SORAFENIB
5 AXITINIB 73 58% 3% 83 Search AXITINIB Search AXITINIB
6 TEMSIROLIMUS 61 39% 4% 122 Search TEMSIROLIMUS Search TEMSIROLIMUS
7 PAZOPANIB 56 44% 3% 97 Search PAZOPANIB Search PAZOPANIB
8 CYTOREDUCTIVE NEPHRECTOMY 55 77% 1% 37 Search CYTOREDUCTIVE+NEPHRECTOMY Search CYTOREDUCTIVE+NEPHRECTOMY
9 TYROSINE KINASE INHIBITORS 33 11% 10% 288 Search TYROSINE+KINASE+INHIBITORS Search TYROSINE+KINASE+INHIBITORS
10 RENAL CELL CANCER 27 20% 4% 119 Search RENAL+CELL+CANCER Search RENAL+CELL+CANCER

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 SUNITINIB 475 51% 23% 657
2 SORAFENIB 171 30% 17% 484
3 INTERFERON ALPHA 171 15% 38% 1079
4 SU11248 89 44% 5% 154
5 CYTOREDUCTIVE NEPHRECTOMY 83 61% 3% 88
6 FACTOR TARGETED THERAPY 73 76% 2% 51
7 TEMSIROLIMUS 64 45% 4% 106
8 GLOBAL EVALUATION TRIAL 44 81% 1% 26
9 DAYS ON 7 DAYS 39 53% 2% 52
10 AXITINIB 34 65% 1% 32

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLINICAL GENITOURINARY CANCER 21 19% 3% 98

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer 2015 9 42 98%
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials 2015 5 54 56%
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma 2015 2 18 100%
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials 2011 80 26 81%
Optimal Management of Metastatic Renal Cell Carcinoma: Current Status 2013 32 73 77%
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies 2012 70 80 55%
Treatment selection in metastatic renal cell carcinoma: expert consensus 2012 37 65 91%
Comparing comparators: a look at control arms in kidney cancer studies over the years 2015 1 21 90%
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials 2014 13 42 69%
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature 2014 10 32 81%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SOLID TUMOR ONCOL UROL 18 67% 0.6% 16
2 SOLID TUMOR ONCOL 13 15% 2.9% 82
3 KIDNEY CANC 10 61% 0.4% 11
4 CLIN HEMATOL HEMOSTASIS ONCOL STEM CELL TRANSPL 10 63% 0.4% 10
5 KIDNEY CANC PROGRAM 8 50% 0.4% 12
6 RADIOL ONCOL HUMAN PATHOL 6 40% 0.4% 12
7 MED ONCOL EXPT THER EUT 6 24% 0.8% 22
8 GENITOURINARY ONCOL SERV 4 11% 1.4% 39
9 CIC 005 4 75% 0.1% 3
10 LANK GENITOURINARY ONCOLDANA FARBER CANC INS 4 75% 0.1% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000149799 RENAL CELL//RADICAL NEPHRECTOMY//FUHRMAN GRADING
2 0.0000141670 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
3 0.0000121209 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
4 0.0000097042 DIARYLAMIDE//VEGFR 2 INHIBITOR//KDR KINASE
5 0.0000093049 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
6 0.0000086296 RECIST//RECIST 11//TUMOR MEASUREMENT
7 0.0000077383 BAP1//BRCA1 ASSOCIATED PROTEIN 1//SETD2
8 0.0000075107 ANAPLASTIC THYROID CANCER//ANAPLASTIC THYROID CARCINOMA//LENVATINIB
9 0.0000074985 OREGOVOMAB//AFLIBERCEPT//GI PERFORATION
10 0.0000074939 GIRENTUXIMAB//G250//MONOCLONAL ANTIBODY CG250